PT  - JOURNAL ARTICLE
AU  - Gorski, Mathias
AU  - Grunin, Michelle
AU  - Herold, Janina M.
AU  - Fröhlich, Benedikt
AU  - Behr, Merle
AU  - Wheeler, Nicholas
AU  - Bush, William S.
AU  - Song, Yeunjoo E.
AU  - Zhu, Xiaofeng
AU  - Blanton, Susan H.
AU  - Pericak-Vance, Margaret A.
AU  - Heid, Iris M.
AU  - Haines, Jonathan L.
AU - International Age-related Macular Degeneration Genomics Consortium
TI  - Diverse ancestry GWAS for advanced age-related macular degeneration in TOPMed-imputed and Ophthalmologically-confirmed 16,108 cases and 18,038 controls
AID  - 10.1101/2024.11.08.24316962
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.11.08.24316962
4099  - http://medrxiv.org/content/early/2024/11/11/2024.11.08.24316962.short
4100  - http://medrxiv.org/content/early/2024/11/11/2024.11.08.24316962.full
AB  - Age-related macular degeneration (AMD) is a leading cause of blindness with $344 billion dollars global costs. In 2016, the International Age-related Macular Degeneration Genomics Consortium devised genomic data on ∼50,000 individuals (IAMDGC 1.0) and identified 52 variants across 34 loci associated with advanced AMD in European ancestry. We have now analyzed a more densely imputed version (IAMDGC 2.0) and performed cross-ancestry GWAS in 16,108 advanced AMD cases and 18,038 AMD-free controls. This identified 28 loci at P<5×10−8, including two additional AMD loci compared to IAMDGC 1.0 (SERPINA1 and CPN1). Fine-mapping supported one ancestry-shared signal around HTRA1/ARMS2 and nine signals around CFH without African ancestry contribution. The 52-variant genetic risk score with and the 44-variant score without CFH-variants predicted advanced AMD not only in EUR, but also in AFR and ASN (AUC=0.80/0.75, 0.65/0.64, 0.80/0.79, respectively). Our results indicate that the genetic underpinning of advanced AMD is mostly shared between ancestries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UWA, LEI & Flinders group acknowledges financial support for participant recruitment and sample processing provided by the National Health and Medical Research Council (NHMRC) of Australia (#1023911), the Ophthalmic Research Institute of Australia, the BrightFocus Foundation and a Ramaciotti Establishment Grant. CERA receives Operational Infrastructure Support from the Victorian Government. KPB, JEC and AWH are supported by NHMRC Fellowships. The authors acknowledge the support of B. Usher-Ridge, L. Palmer, L Ma and DL Lim in patient recruitment and data collection. The Pittsburgh group acknowledges funding to MBG from NIH/NEI R01 EY09859, Research to Prevent Blindness (N.Y, N.Y.), Harold and Pauline Price Foundation. The Cambridge group was supported by the Medical Research Council, UK (grant G0000067 to JRWY, ATM), the Macular Disease Society (JRWY, ATM); the Guide Dogs for the Blind Association (ATM, JRWY) and the Department of Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology. We thank the clinicians who helped with recruitment, the Reading Centre at Moorfields Eye Hospital, London for grading fundus photographs and the subjects who participated in the research. The EUGENDA-Cologne group was supported by a grant from the Retinovit foundation. The Vanderbilt group was supported by the National Institutes of Health Grants AG019085 (JLH), EY023164 (JLH), EY022310 (JLH), EY012118 (JLH, AA, MAB), AG044089 (JDH), T32 EY007157 (JNCB) and a PhRMA Informatics fellowship (JNCB). The MMAP-Penn group was supported by the Arnold and Mabel Beckman Initiative for Macular Research (CAC), Research to Prevent Blindness Inc (CAC), EyeSight Foundation of Alabama (CAC), and NIH EY023164 (DS). The Oregon group was supported by National Eye Institute grants EY021532, and EY0105712, and an unrestricted departmental grant from Research to Prevent Blindness. The Edinburgh group using the Scottish AMD study was funded by the Chief scientists Office (Scotland) CSO reference number: CZB/4/79 and would like to thank Alan Wright, Ana Armbrecht and Fraser Imrie for collecting the samples and all of the individuals who participated in this study. The EU/JHU study acknowledges the support of the CEPH Biological Resource Centre by the French Ministere de l'Enseignement Superieur et de la Recherche, Foundation Fighting Blindness Clinical Research Institute (FFB, CRI), an unrestricted grant to the Wilmer Eye Institute from Research to Prevent Blindness, and Baylor-Johns Hopkins Center for Mendelian Genetics (National Human Genome Research Institute, NHGRI/NIH; 1U54HG006542-01). The Jerusalem study was supported by grants from the Israel Science fund (ISF) and the Israeli Ministry of Health. The Southampton study acknowledges Southampton Wellcome Trust Clinical Research Facility for research nurse support in collecting DNA samples, Helen Griffiths (Clinical and Experimental Sciences, University of Southampton) for technical support in processing DNA and all the patients who contributed to this work. AJL supported at the University of Southampton by funding from The Wellcome Trust (076169/A), American Health Assistance Foundation (M2007110), Macula Vision Research Foundation, TFC Frost Charitable Trust, Brian Mercer Charitable Trust, Macular Society, Hobart Trust and the Gift of Sight appeal. The Marshfield group was supported by grants NIH NCATS: UL1TR000427, NIH NHGRI: 1U01HG006389, and support from the Marshfield Clinic Research Foundation. The Melbourne study was supported by the National Health and Medical Research Council Australia, project grant 1008979, Centre for Clinical Research Excellence #529923 - Translational Clinical Research in Major Eye Diseases. NHMRC Research Fellowship (PNB, #1028444). CERA receives Operational Infrastructure Support from the Victorian Government. The Miami group was supported by National Institutes of Health Grants R01 EY012118 (MAP-V, WKS, JLK, SGS, MDC), EY023164 (MAP-V, WKS, JLH, MAP-V), EY022310 (MAP-V) and T32 EY023194 (RJS) and P30-EY005722. All Bascom Palmer Eye Institute authors are partially supported by NIH Center Core Grant P30EY014801 and an unrestricted grant from Research to Prevent Blindness, New York, NY, USA. The MMAP-Michigan and AREDS groups were supported by Intramural Research Program of the National Eye Institute (ZO1 EY000475); the AREDS study was supported by the National Eye Institute/National Institutes of Health, (contract no.: HHS-NOI-EY-0-2127), Bethesda Maryland; the AREDS2 study was supported by the intramural program funds and contracts from the National Eye Institute/National Institutes of Health (NEI/NIH), Department of Health and Human Services, Bethesda, MD. Contract No. HHS-N-260-2005-00007-C. ADB Contract No. N01-EY-5-0007. The Michigan study was supported by the National Eye Institute (EY0022005) and the National Human Genome Research Institute (HG006513 HG007022), Foundation Fighting Blindness and National Institutes of Health/National Eye Institute Grant-EY016862. The NHS/HPF studies were supported by EY021900, EY017362, EY13824, EY009611, CA87969, CA49449, and HL35464. The Regensburg group was supported by BMBF-01ER1206 (to IMH), EFKS 2012_A147 (IMH), BMBF-01GP1308 (IMH), the Deutsche Forschungsgemeinschaft (grant WE 1259/19-1 and WE1259/19-2, BHFW), and the Alcon Research Institute (BHFW). The Regensburg Team would also like to thank Randy Rueckner for technical assistance. The Rotterdam-Clinic study was supported by ZoNMW project number: 170885606, MDfonds, Landelijke Stichting voor Blinden en Slechtzienden (LSBS). The UCSD study was supported by grants from NIH (grants EY014428, EY018660, P30EY022589), 863 Program (2014AA021604), and Research to Prevent Blindness. ZS is supported by 863 Program (2014AA021604), ZY is supported by National Natural Science Foundation of China (81170883 and 81430008), KZ is supported by NIH grants (1R01EY018660-01A10) and VA Merit Award. The EUGENDA-Neijmegen study was supported by MD Fonds, Gelderse Blindenstichting, Algemene Vereniging ter Voorkoming van Blindheid, Stichting Nederlands Oogheelkundig Onderzoek, Oogfonds. The Utah study was supported by the ALSAM Foundation, an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology and Visual Sciences, University of Utah, SOM, Moran Eye Center. The Seoul National University Bundang group was supported by grants from the National Research Foundation of Korea, funded by the Ministry of Education, Science, and Technology (grant numbers; NRF-2009-0072603 and NRF-2012R1A1A2008943). The Westmead/Sydney samples were collected in three studies that were supported by the National Health and Medical Research Council (NHMRC), Australia: Grant IDs 974159, 211069, 457349 and 512423 supported the Blue Mountains Eye Study that provided population-based controls; Grant ID 302010 supported the Cataract Surgery and Risk of Age-related Macular Degeneration study that provided clinic-based early and late AMD cases and controls; and Grant ID 571013 supported the Genes and Environment in late AMD study that provided clinic-based late AMD cases. NHMRC Senior Research Fellowship (JJW, 358702, 632909). NHMRC Senior Research Fellowship (JJW, 358702, 632909). The NHMRC had no role in the design or conduct of these studies. The Columbia study was supported by the National Institutes of Health/NIH grants R01-EY013435 and P30-EY019007, and Research to Prevent Blindness (New York, NY). The CWRU group was supported by VA Merit Review (NSP), Foundation Fighting Blindness (SAH), Research to Prevent Blindness (SAH); International Retinal Research Foundation (SKI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data was collected according to Declaration of Helsinki principles. Study participants provided informed consent, and protocols were reviewed and approved by local ethics committees.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes